

## 2023 Bioshares Biotech Summit – Speaker List

Keynote Address

**Yuman Fong**

Sangiocomo Chair and Chair of the Department of Surgery at City of Hope Medical Centre, inventor of the oncolytic virus CF33 (licensed to Imugene)

Chris Behrenbruch, CEO of **Telix Pharmaceuticals**, market capitalisation \$3.4 billion (5 June 2023), ttm sales of first product Illuccix \$247 million.

John Pilcher, CEO of **Neuren Pharmaceuticals**, market capitalisation \$1.7 billion, first drug product Daybue (trofinetide) approved by FDA and launched in April 2023.

David Hoey, President & CEO of **Vaxxas** (Private), revolutionising global vaccine delivery, \$230 million in funding from partners, governments, and investors secured to date, employing 130 Staff in Brisbane and US.

Monil Shah, CBO of **Imugene**, market capitalisation \$674 million, developing suite of novel cancer immunotherapy products

Teri Thomas, CEO and MD of Volpara Health Technologies, market capitalisation \$180 million, global leader breast density assessment.

James Agnew, CFO of **Aroa BioSurgery**, generated sales of NZ\$61 million (up 55%) from suite of biologic wound healing products.

Andrew Shute, Senior VP of BD for **EBR Systems**, developing the world's first and only wireless electronic heart pacing system for the left ventricular, market capitalisation \$310 million. Product to be filed for FDA approval.

Nina Webster, CEO of **Dimerix**, conducting Phase III study in FSGS, orphan kidney disease.

Hugh Alsop, CEO of **Kinosis Therapeutics** (Private), developing a treatment for substance use disorders and other neurological/psychiatric disorders, signed \$273 million deal with Boehringer Ingelheim May 2023.

Steven Gourlay, CEO of **Actinogen**, with 160 patient Phase IIa study in depression underway and 330 patient Phase IIb study in Alzheimer's due to commence. Market capitalisation \$84 million.

Matt Callahan, Executive Director of **Botanix Pharmaceuticals**, awaiting FDA review and approval (Q3 2023) for first product for treatment of excessive sweating, already approved in Japan. Market capitalisation \$118 million.

Kingsley Hall, CEO of **Micro-X**, and Anthony Skeats, COO of **Micro-X**, developed first and only commercial cold cathode x-ray tube, first product on market for mobile x-rays, second product, the Argus, to be launched in 2023 for bomb detection, and third product for brain imaging to be ready for testing next year. Market capitalisation \$51 million.

Luke Reid, CEO of **Microba**, listed in 2022, developing therapeutics from microbiome plus microbiome testing business operational. Signed strategic partnership with Sonic Healthcare last year which has taken 20% stake in business. Market capitalisation \$83 million.

Liz Dallimore, CEO of **Argenica**, developing neuroprotective agent for treatment following stroke.

Gary Phillips, CEO of **Pharmaxis**. Clinical programs for scar treatment and myelofibrosis. Market capitalisation \$39 million.

Steven Yatomi-Clarke, CEO of **Prescient Therapeutics**, developing CAR-T cell technologies and small molecule therapies for oncology indications.

Michael Baker, CEO and MD of **Arovella Therapeutics**, developing a range of cell therapies for multiple oncology applications.

Malcolm Hebblewhite, CEO and MD of **Atmo Biosciences** (Private), undertaking pivotal US study for gut gas sensing capsule to gain FDA approval.

Jeremy Steele, CEO of **Control Bionics**, developing Neuro-Node to assist with brain-muscle control in patients with paralysis or loss of speech.

Steven Lydeamore, CEO of **Immuron**, selling Travelan and Protectyn, multiple clinical programs for GI disorders underway or due to commence.

Richard Lipscombe, CEO of **Proteomics International**, developing novel diagnostics, including lead program in early diagnosis of diabetic kidney disease.

Otto Buttula, Executive Chairman of **Rhythm Biosciences**, developing ColoSTAT, a blood-based test to aid in the detection of colorectal cancer.

Sander Bangma, CEO of **Navier Medical** (Private), commercialising software for assessment of coronary arteries including the presence of microcalcification and grading risk of potential heart attacks.

Marjan Mikel, CEO of **Respiri**, commercialising remote patient management product via smartphone, assessing wheezing in patients with asthma, COPD and other respiratory conditions.